Evaxion A/S ADR Dossier
Qualitative Analysis
Business overview
Evaxion A/S (formerly Evaxion Biotech A/S) is a clinical-stage TechBio company pioneering the development of novel immunotherapies and vaccines using its proprietary AI-Immunology™ platform. The platform leverages artificial intelligence, machine learning, and digital twin technology to decode the human immune system, enabling the rapid discovery and design of highly targeted vaccines for cancer and infectious diseases. Evaxion's pipeline includes personalized cancer vaccines (such as EVX-01), off-the-shelf oncology candidates (EVX-04), and prophylactic vaccines targeting bacterial and viral pathogens (such as EVX-B3 and EVX-B4). By shifting the drug discovery paradigm from traditional trial-and-error methods to predictive computational modeling, Evaxion aims to significantly improve clinical success rates and accelerate development timelines.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Leveraging the unique scalability of the AI-Immunology platform to expand into the discovery and development of drug candidates targeting autoimmune diseases (AIDs) [1.4.1].
Expected impact: Increases the pool of diseases for which Evaxion can potentially discover and develop new treatments, expanding the addressable market and partnership opportunities.
Active pursuit of parallel partnership discussions based on external interest in both the AI-Immunology platform and the R&D pipeline assets.
Expected impact: Aims to secure at least one more partnership deal to generate upfront option fees, milestone payments, and non-dilutive funding to extend the cash runway.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Out-licensing of infectious disease vaccine candidate EVX-B3, transferring all future development costs to MSD.
Terms: Evaxion received a $7.5 million option exercise fee and is eligible for future milestone payments of up to $592 million.
Collaborating to design a new polio vaccine concept using the AI-Immunology platform.
Terms: Supported by grant funding from the Gates Foundation.